Peptency Academy · Research progress
ANSM peptide alert, update of 31 Aug 2026: a police sanitaire decision on a retatrutide product
On 31 Aug 2026 ANSM added to its alert on peptides sold online a decision of 14 Aug 2026 that suspends the sale of a product presented as containing retatrutide, although the seller's website marked it for laboratory use only. Source sentence
Alert: "Actualisation du 31/08/2026 Nouvelle mesure de police sanitaire ... Est concerné le produit dénommé ... présenté comme contenant du retatrutide."; decision: "la mention « A usage exclusif dans un environnement de laboratoire » apparaît sur la présentation du produit"1 ANSM, 2 July 2026, updated 31 August 20262 ANSM police sanitaire decision of 14 August 2026 ANSM is France's national agency for the safety of medicines and health products (Agence nationale de sécurité du médicament et des produits de santé). Source sentence
"l'Agence nationale de sécurité du médicament et des produits de santé (ANSM)"2 ANSM police sanitaire decision of 14 August 2026 Retatrutide, the substance named in the decision, is a GLP-1 receptor agonist peptide (PubChem CID 171390338). Source sentence
"présenté comme contenant du retatrutide, un aGLP-1"; PubChem PUG REST: substance records named retatrutide (for example SID 438519203) map to CID 171390338; MolecularFormula C221H342N46O68; MolecularWeight 47312 ANSM police sanitaire decision of 14 August 20263 PubChem CID 171390338
Regulatory content shown for: EU and UK.
Research progressAcademy31 August 2026Regulator action
What happened
France
- The alert was published on 2 Jul 2026 and updated on 22 Jul 2026 and 31 Aug 2026. Source sentence
"PUBLIÉ LE 02/07/2026 - MIS À JOUR LE 31/08/2026"; "Actualisation du 22/07/2026"
1 ANSM, 2 July 2026, updated 31 August 2026 - The decision, published on 31 Aug 2026, suspends the placing on the market, import, export, exploitation and advertising of that product by AZRL LTD and orders its withdrawal. Source sentence
"Décision portant suspension de la mise sur le marché ... de l'importation, de l'exportation, de l'exploitation et de la publicité du produit ... ainsi que le retrait de ce produit en tout lieu où il se trouve"
2 ANSM police sanitaire decision of 14 August 2026 - The decision records the line "A usage exclusif dans un environnement de laboratoire" (for laboratory use only) on the seller's website and still finds that the product meets the definition of a medicinal product by presentation and by function under article L.5111-1 of the French public health code. Source sentence
"la mention « A usage exclusif dans un environnement de laboratoire » apparaît sur la présentation du produit sur le site internet de la société AZRL LTD"; "répond à la définition de médicament par présentation et par fonction au sens de l'article L. 5111-1 du CSP"
2 ANSM police sanitaire decision of 14 August 2026 - The alert also links two earlier police sanitaire decisions on products presented as GLP-1 agonists: 9 Jul 2026 (Synedica Laboratories) and 16 Jul 2026 (AZRL LTD). Source sentence
"Décision de police sanitaire du 09/07/2026 - Retrait des produits présentés comme contenant des agonistes du GLP-1 - Société Synedica Laboratories"; "Décision de police sanitaire du 16/07/2026 - Retrait des produits présentés comme contenant des agonistes du GLP-1 - Société AZRL LTD"
1 ANSM, 2 July 2026, updated 31 August 2026 - The alert lists retatrutide, TB500, GHK-Cu, BPC-157 and NAD+ among products offered without authorisation, alongside other names (BP180, GH) that are not Academy catalog compounds. Source sentence
"Parmi les produits proposés sans autorisation des autorités sanitaires, on trouve par exemple le rétatrutide, le BP180, le TB500, le GH, le GHK-Cu, le BPC-157, le NAD+, etc."
1 ANSM, 2 July 2026, updated 31 August 2026
Why it matters for researchers
- The decision applies the medicinal product test by presentation and by function, the same two limbs as Directive 2001/83/EC Article 1(2), to a product carrying a laboratory use only line. Source sentence
"répond à la définition de médicament par présentation et par fonction au sens de l'article L. 5111-1 du CSP"
2 ANSM police sanitaire decision of 14 August 20264 Directive 2001/83/EC, Article 1(2) - The alert tells the public never to use a product marked "For research use only" or "Réservé à la recherche", among other such lines. Source sentence
"N'utilisez jamais un produit qui porte la mention « For research use only » ou « Réservé à la recherche » ou ..."
1 ANSM, 2 July 2026, updated 31 August 2026
What is not known
- The alert names TB500 without a sequence or a mass, so it does not state whether it means thymosin beta 4 or the 7 residue fragment Ac-LKKTETQ. Source sentence
"le TB500" (no sequence, mass or CAS number on the page)
1 ANSM, 2 July 2026, updated 31 August 2026 - Neither the alert nor the decision reports laboratory analysis of the products. Source sentence
Alert and decision texts, full pages read 13 Oct 2026
1 ANSM, 2 July 2026, updated 31 August 20262 ANSM police sanitaire decision of 14 August 2026 - The alert states that other measures are in progress without naming them. Source sentence
"D'autres mesures sont en cours."
1 ANSM, 2 July 2026, updated 31 August 2026
Regulator actions
France
- , France, ANSM, injunction: Suspension of placing on the market, import, export, exploitation and advertising, and withdrawal, of a product presented as containing retatrutide. 2 ANSM police sanitaire decision of 14 August 2026
- , France, ANSM, alert: Alert on peptides sold online updated with a new police sanitaire decision. 1 ANSM, 2 July 2026, updated 31 August 2026
Sources
- 1ANSM, 2 July 2026, updated 31 August 2026 accessed 13 Oct 2026
- 2ANSM police sanitaire decision of 14 August 2026 accessed 13 Oct 2026
- 3PubChem CID 171390338 accessed 13 Oct 2026
- 4Directive 2001/83/EC, Article 1(2) accessed 12 Oct 2026
About this page
Research-use information. This library summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
Reviewed by the Peptency editorial process. Version 1, last edited 13 October 2026, 4 sources.
Cite this page: Peptency Academy. ANSM peptide alert update, 31 Aug 2026: a retatrutide product. Version 1./eu/academy/news/ansm-peptide-alert-update-august-2026/